Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The system is powered by BrainSense technology, which has received approval from USFDA
Milestone marks a major leap toward real-time, personalised neuromodulation therapy as India’s Parkinson’s burden rises sharply
Punya Salila Srivastava commends sanitation, waste management and infection control measures, while inaugurating a new G+9 undergraduate girls’ hostel
Subscribe To Our Newsletter & Stay Updated
